Investigations of the biomechanical changes in the optic nerve head may eventually lead to improvements in therapies for patients with glaucoma.
Patient selection is the key factor in obtaining the best visual outcomes after cataract surgery and intraocular lens implantation.
Innovations in sustained-drug delivery and neuroprotection are bringing glaucoma specialists one step closer to additional therapeutic options.
Staging patients based on their ocular pathologies using the most advanced diagnostic tools can result in excellent image quality by precisely establishing the need for lens- or corneal-based procedures.
Aphakic eyes that have no or inadequate capsular support can pose a significant challenge to cataract surgeons. Careful attention to the preoperative considerations, appropriate intraocular lens choices, surgical techniques, and postoperative management can ensure optimal results.
An analysis of U.S. claims data reveals a substantial proportion of patients (17%) remained untreated 4 years after their initial diagnosis of open-angle glaucoma.
A hot topic in cataract surgery is alternative ways to administer perioperative medications with the goal of lowering the incidence of cystoid macular edema (CME). One way to achieve that goal would be the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and transzonular steroids.
A corneal inlay (Kamra, AcuFocus) for presbyopia seems to be a good treatment option for emmetropic and ametropic presbyopic patients, as well as for presbyopic patients who underwent a previous LASIK procedure, said Minoru Tomita, MD, PhD.
The absence of glistening formation is among the advantages associated with new IOL technology, relates one ophthalmologist.